A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon ® ) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP ® ) in a fixed-dose regimen in women undergoing ovarian stimulation

By Hoomans Eric H.M.  

Human Reproduction, Vol. 14, Iss. 10, 1999-10 ,pp. : 2442-2447

Oxford University Press

Access to resources Recommend Favorite

Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial

By Kamischke A  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 596-603

Oxford University Press

Access to resources Recommend Favorite

Infertility. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial

By Borm G.   Mannaerts B.  

Human Reproduction, Vol. 15, Iss. 7, 2000-07 ,pp. : 1490-1498

Oxford University Press

Access to resources Recommend Favorite

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients

By Jansen CAM  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 2995-2999

Oxford University Press

Access to resources Recommend Favorite